Form 4: Crinetics Pharmaceuticals COO Jeff E. Knight Sells Shares
SEC Form 4 Filing
Jeff E. Knight, Chief Operating Officer of Crinetics Pharmaceuticals, sold 956 shares of common stock on June 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On June 26, 2024, Jeff E. Knight, the Chief Operating Officer of Crinetics Pharmaceuticals, sold 956 shares of common stock at a price of $44.38 per share.
- The sale was executed automatically under a Rule 10b5-1 trading plan previously adopted by Knight.
- Following the transaction, Knight still beneficially owns 52,580 shares of Crinetics Pharmaceuticals, which includes 956 shares acquired under the Issuer's Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine stock sale by an executive under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.
Industry Context
Sales by company executives are a normal part of corporate governance. Investors often look to the reasons behind the sale, such as diversification or personal financial planning.
Stakeholder Impact
- The sale of shares by a company executive could be perceived neutrally or slightly negatively by shareholders, depending on the context and the size of the sale.
Key Dates
| Date | Description |
|---|---|
| 06/26/2024 | Date of stock sale transaction |
| 06/28/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.